Jason Mast
@jasonmast.bsky.social
Covering science, medicine & business for STAT
Reach out on Signal: JasonMast.05
Reach out on Signal: JasonMast.05
I'd start by reading about Brooke Kajdy, a 24-year-old with aggressive lymphoma, desperately waiting -- and waiting and waiting -- on a trial for a cutting edge treatment regimen to start
April 25, 2025 at 1:18 PM
I'd start by reading about Brooke Kajdy, a 24-year-old with aggressive lymphoma, desperately waiting -- and waiting and waiting -- on a trial for a cutting edge treatment regimen to start
And, amid a bubble, investors spent lavishly on companies and proects that were, well, maybe less than fully conceived...
February 10, 2025 at 5:24 PM
And, amid a bubble, investors spent lavishly on companies and proects that were, well, maybe less than fully conceived...
ICYMI last week we published a detailed look into the meteoric boom and bust of the CRISPR industry
A decade ago, the powerful gene editing tool promised to change medicine. And arguably, it delivered. Casgevy, a curative drug, for sickle cell is now available
And yet:
A decade ago, the powerful gene editing tool promised to change medicine. And arguably, it delivered. Casgevy, a curative drug, for sickle cell is now available
And yet:
February 10, 2025 at 5:22 PM
ICYMI last week we published a detailed look into the meteoric boom and bust of the CRISPR industry
A decade ago, the powerful gene editing tool promised to change medicine. And arguably, it delivered. Casgevy, a curative drug, for sickle cell is now available
And yet:
A decade ago, the powerful gene editing tool promised to change medicine. And arguably, it delivered. Casgevy, a curative drug, for sickle cell is now available
And yet: